All News
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.
SUA <300 μmol/L at Week 36:
63.8% vs 40.7% (p<0.0001)
A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile
Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Do probiotics improve disease activity in PsA?
POS0290: no
MEDISPA RCT n=66
Multispecies probiotics not superior to placebo at week 12
#EULAR2026 @RheumNow https://t.co/1byJ1nB4GF
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype
Results from the Spanish REGISPON-3
POS1352
#EULAR2026 @RheumNow https://t.co/XicguAdXJ1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
How many patients with IBD have axSpA?
POS1338 #EULAR2026 @RheumNow
⬇️⬇️⬇️ https://t.co/29qkrCnDYz
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?
Yes! POS 1347
Multicenter randomised open-label trial
N=56
#EULAR2026 @RheumNow https://t.co/kP7ropPkpC
Nelly ZIADE 🍀 Nellziade ( View Tweet)
What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?
Data from 194 patients from the SELECT-AXIS2 RCT:
▶️ Remission maintained in 1/4 at48 weeks
POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk:
-VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile)
-No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t
Links:
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://twitter.com/eular_ard/status/2062509665024344391
Janet Pope Janetbirdope ( View Tweet)
LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
First head-to-head trial to show #PsA joint outcome superiority
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD
Jiha Lee JihaRheum ( View Tweet)
Abstr LB0003
Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered.
RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD.
Curious about long term results and potential position in tx strategies
LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO
Links:
sheila RHEUMarampa ( View Tweet)
Abstr LB0004
CC312 is a CD19/CD3/CD28 tri-specific T cell engager and sustains SRI-4 responses beyond one year with rapid, deep B-cell depletion in autoimmune diseases. Not CAR-T. Not a conventional biologic. A T cell engager that redirects your own immune cells to deplete B https://t.co/rTs3Rg7BPe
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
CAR-T without the CAR-T risks?
AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN
Jiha Lee JihaRheum ( View Tweet)
#SLE Rx options
Determining #MOA
#TYK2 #sig w #deucravacitinib
#IFN sig in active #SLE
⬇️ in
#anifrolumab
#upa
#deucra
#repeat renal #bx in #obinutuzimab ➡️
Clears B cells
#Dapriluzimab & other MOAs
⬇️AntiDNA
⬆️complements
#EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336
Janet Pope Janetbirdope ( View Tweet)
